# LIMBER-304 (NCT04551053)

> To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

No report yet. It can be ordered.

- Drugs tested: parsaclisib plus ruxolitinib
- Indication: myelofibrosis with suboptimal response to ruxolitinib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04551053
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Incyte Corporation
- Conditions: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
- Interventions: parsaclisib; ruxolitinib; placebo
- Enrollment: 177
- Primary outcome: Percentage of Participants Achieving ≥25% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging (MRI) (or Computed Tomography [CT] Scan in Applicable Participants)

## Indexed commentary on LIMBER-304 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=limber-304-nct04551053